STEPAN COMPANY Research and Development Expense
STEPAN COMPANY (SCL) reported Research and Development Expense of $34.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-02-26
- STEPAN COMPANY research and development expense for fiscal 2025 was $34.80M, a 3.74% increase from fiscal 2024.
- STEPAN COMPANY research and development expense for fiscal 2024 was $33.54M, a 6.12% decline from fiscal 2023.
- STEPAN COMPANY research and development expense for fiscal 2023 was $35.73M, a 12.64% decline from fiscal 2022.
- STEPAN COMPANY research and development expense for fiscal 2022 was $40.90M, a 5.48% increase from fiscal 2021.
| Period end | Research and Development Expense 12 month |
|---|---|
| 2025-12-31 | $34.80M 10-K · filed 2026-02-26 |
| 2024-12-31 | $33.54M 10-K · filed 2026-02-26 |
| 2023-12-31 | $35.73M 10-K · filed 2026-02-26 |
| 2022-12-31 | $40.90M 10-K · filed 2025-02-27 |
| 2021-12-31 | $38.78M 10-K · filed 2024-02-29 |
| 2020-12-31 | $36.00M 10-K · filed 2023-02-28 |
| 2019-12-31 | $34.14M 10-K · filed 2022-02-25 |
| 2018-12-31 | $33.52M 10-K · filed 2021-02-26 |
| 2017-12-31 | $33.17M 10-K · filed 2020-02-27 |
| 2016-12-31 | $34.86M 10-K · filed 2019-02-27 |
| 2015-12-31 | $30.32M 10-K · filed 2018-02-27 |
| 2014-12-31 | $27.24M 10-K · filed 2017-02-24 |
| 2013-12-31 | $28.78M 10-K · filed 2016-02-24 |
| 2012-12-31 | $28.03M 10-K · filed 2015-02-27 |
| 2011-12-31 | $25.13M 10-K · filed 2014-02-26 |
| 2010-12-31 | $24.22M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Longevity Health Holdings, Inc. (XAGE) | United States | $0.006B | -0.09 |
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| ECOLAB INC. (ECL) | United States | $77.183B | 36.58 |
| PROCTER & GAMBLE Co (PG) | United States | $338.763B | 21.26 |